USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. decreased its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,546,690 shares of the company's stock after selling 55,795 shares during the quarter. Vanguard Group Inc. owned 8.11% of USANA Health Sciences worth $55,511,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Pzena Investment Management LLC lifted its stake in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after purchasing an additional 37,466 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of USANA Health Sciences by 8.8% during the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock worth $21,247,000 after purchasing an additional 47,745 shares during the last quarter. State Street Corp increased its position in shares of USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company's stock worth $16,501,000 after purchasing an additional 2,782 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of USANA Health Sciences by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company's stock valued at $11,269,000 after purchasing an additional 12,898 shares during the last quarter. Finally, American Century Companies Inc. increased its position in USANA Health Sciences by 12.3% during the fourth quarter. American Century Companies Inc. now owns 233,797 shares of the company's stock worth $8,391,000 after buying an additional 25,522 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Joshua Foukas sold 5,732 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mulham Mulham sold 3,234 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now directly owns 12,775 shares in the company, valued at $421,319.50. This represents a 20.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,920 shares of company stock valued at $500,285. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on USNA shares. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th.

USANA Health Sciences Stock Performance

NYSE:USNA traded up $0.13 during mid-day trading on Thursday, reaching $23.56. The stock had a trading volume of 26,177 shares, compared to its average volume of 192,535. USANA Health Sciences, Inc. has a twelve month low of $23.26 and a twelve month high of $49.78. The business has a 50 day simple moving average of $28.73 and a 200 day simple moving average of $33.76. The firm has a market capitalization of $445.40 million, a price-to-earnings ratio of 8.33, a PEG ratio of 0.93 and a beta of 1.00.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. As a group, sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.